{"organizations": [], "uuid": "9d41813511811fd617a4a26542a84457fe3b30eb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-karyopharm-therapeutics-announces/brief-karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-idUSASC09YSZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T00:42:00.000+03:00", "replies_count": 0, "uuid": "9d41813511811fd617a4a26542a84457fe3b30eb"}, "author": "", "url": "https://www.reuters.com/article/brief-karyopharm-therapeutics-announces/brief-karyopharm-therapeutics-announces-proposed-public-offering-of-common-stock-idUSASC09YSZ", "ord_in_thread": 0, "title": "BRIEF-Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-karyopharm therapeutics announces proposed public offering of common stock may", "sentiment": "negative"}, {"name": "karyopharm therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "offering of common stock reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Karyopharm Therapeutics Inc:\n* KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK\n* COMMENCEMENT OF A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION IN SHARES OF ITS COMMON STOCK\n* INTENDS TO USE NET PROCEEDS OF OFFERING TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF SELINEXOR\n* TO USE PROCEEDS OF OFFERING TO CONTINUE ESTABLISHING COMMERCIAL INFRASTRUCTURE FOR POTENTIAL LAUNCH OF SELINEXOR IN U.S. Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-05-02T00:42:00.000+03:00", "crawled": "2018-05-02T01:01:12.019+03:00", "highlightTitle": ""}